Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTRAST-NP
2023-508760-29-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Lebrikizumab + background intranasal mometasone with Placebo + background intranasal mometasone (2 arms). Primary endpoints: Mean change from baseline in participant-reported Nasal Congestion Score severity and Mean change from baseline in endoscopic Nasal Polyp Score. Planned start Oct 2024; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2023-508760-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508760-29-00.